Skip to main content
Rohit Jain on Muck Rack

Rohit Jain

Mumbai
As seen in: Medium, ETRealty, Forbes, MSN India, Nature, The Economic Times, Wiley Online Library, Hindustan Times, Cisco Blogs, MDPI and
Views personal

Get in touch with Rohit

Contact Rohit, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

India: Direct and Indirect Tax Update

|
By Rohit Jain
| taxand.com
A newsletter from Economic Laws Practice, Taxand India In its latest edition, tax experts from Economic Laws Practice analyse recent developments in direct and indirect taxes following a series of significant Indian tax rulings that could affect both businesses and individuals. Recent direct tax decisions clarify the treatment of tenancy rights, compensation payments and other capital receipts, providing greater certainty on when certain transactions may fall outside the tax net.
Open in Who Shared Issue with article?

E-learning Platforms are Bringing Concept-Driven Learning to the Center Stage

|
By Rohit Jain
| Higher Education Review Verified
Learning in today’s world has evolved greatly. Digital technology has revolutionized the approach to learning for students and teachers alike. Several EdTech platforms are springing up to make learning digitally accessible. However, certain platforms are going the extra mile to provide students with an after-school learning model that is affordable and engaging.
Open in Who Shared Issue with article?

Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial

|
By Jeffrey Johnson, Justin Miller, Firas Hatoum, Michael J Schell, Xiaoqing Yu, Gabriel Roman Souza, Keerthi Gullapalli, Adnan Fazili, Rohit Jain, Jonathan Chatzkel, Ling Cen, Jasreman Dhillon, Jiqiang Yao, Junmin Whiting, Jiannong Li, Ghazal Jameel, Jingsong Zhang, Xuefeng Wang, Philippe E. Spiess, Mayer N Fishman, Jad Chahoud, Sarah Mizelle, Christopher Cubitt, Jennifer Swank
| Nature Verified
Abstract Prolonged or indefinite systemic therapy remains standard for advanced clear cell renal cell carcinoma (ccRCC), often resulting in cumulative toxicities and treatment burden. We conducted a single-arm phase 2 trial (ClinicalTrials.gov identifier: NCT02964078) of a fixed-duration regimen of anti-PD1 pembrolizumab plus high-dose interleukin-2 in treatment-naive advanced ccRCC. Primary objectives of safety and response were previously reported.
Open in Who Shared Issue with article?
See all 481 licensed articles (483 Total)